Company news
Aptevo Therapeutics Inc. news in 2024
Aptevo Therapeutics Inc.'s news releases, calls and decks from 2024, newest first.
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds
December 11, 2024
Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan
November 28, 2024
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies
November 19, 2024
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update
November 6, 2024
Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
September 17, 2024
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
September 15, 2024
Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study
September 15, 2024
Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update
August 7, 2024
Aptevo Therapeutics Announces Closing of $2.75 Million Offering
June 30, 2024
Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules
June 27, 2024
Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update
May 7, 2024
Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering
April 14, 2024
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
April 10, 2024
Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update
March 4, 2024
Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan
March 3, 2024